Fresenius SE & CO KGaA : Q2 2018 results: Group EBIT in line; EBIT outlook raised for Kabi, but group outlook confirmed
>Q2 2018 results: sales in line with expectations, hit by FX headwinds - FSE posted its Q2 2018 results today (31 July). Revenues came in at € 8,382m, a touch below our estimate (€ 8,414m) and consensus (€ 8,434m). (Note: all references to consensus indicate Vara consensus.) Adj. EBIT stood at € 1,145m, slightly above consensus (€ 1,133m) and in line with our estimate (€ 1,146m).Management raised its full-year 2018 EBIT outlook for Kabi to a growth range of -2% t...Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.